Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Merck_KGa_A's_biosimilars_business
Baxter's infusion systems business Baxter's IV solutions business Glenveigh Pharmaceuticals Roche's intravenous drug business |
| gptkbp:acquisition |
gptkb:Merck_KGa_A's_biosimilars_business
Baxter International's infusion systems business Glenveigh Pharmaceuticals |
| gptkbp:awards |
awarded for sustainability efforts
recognized for innovation in healthcare received multiple industry awards awarded for corporate social responsibility |
| gptkbp:ceo |
gptkb:Michael_Sen
|
| gptkbp:employees |
over 40,000
|
| gptkbp:focus |
gptkb:medical_devices
biosimilars transfusion medicine infusion therapy generic pharmaceuticals parenteral nutrition |
| gptkbp:founded |
gptkb:1999
|
| gptkbp:headquarters |
Bad Homburg vor der Höhe
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fresenius Kabi AG
|
| gptkbp:industry |
healthcare
|
| gptkbp:operates_in |
more than 100 countries
|
| gptkbp:parent_company |
gptkb:Fresenius_SE_&_Co._KGa_A
|
| gptkbp:part_of |
gptkb:Fresenius_Group
|
| gptkbp:partnership |
gptkb:International_Federation_of_Red_Cross_and_Red_Crescent_Societies
gptkb:World_Health_Organization gptkb:Global_Fund_to_Fight_AIDS,_Tuberculosis_and_Malaria |
| gptkbp:products |
gptkb:medical_devices
clinical nutrition intravenous drugs infusion solutions |
| gptkbp:research |
collaborates with universities
invests in R& D for new products invests in biosimilars development invests in clinical trials invests in medical device innovation |
| gptkbp:revenue |
€6.5 billion (2020)
|
| gptkbp:subsidiary |
Fresenius Kabi Australia Pty Ltd.
Fresenius Kabi Canada Ltd. Fresenius Kabi USA, LLC |
| gptkbp:sustainability |
focus on environmental responsibility
focus on social responsibility focus on governance |
| gptkbp:website |
www.fresenius-kabi.com
|
| gptkbp:bfsParent |
gptkb:B._Braun_Melsungen_AG
|
| gptkbp:bfsLayer |
7
|